Martí Covadonga, Sánchez-Méndez José Ignacio
Breast Cancer Unit, Hospital Universitario La Paz, 28046 Madrid, Spain.
Gynaecology Department, Hospital Universitario La Paz, 28046 Madrid, Spain.
Cancers (Basel). 2021 May 21;13(11):2538. doi: 10.3390/cancers13112538.
Endocrine therapy (ET) has established itself as an efficacious treatment for estrogen receptor-positive (ER+) breast cancers, with a reduction in recurrence rates and increased survival rates. The pre-surgical approach with chemotherapy (NCT) has become a common form of management for large, locally advanced, or high-risk tumors. However, a good response to NCT is not usually expected in ER+ tumors. Good results with primary ET, mainly in elderly women, have encouraged studies in other stages of life, and nowadays neoadjuvant endocrine treatment (NET) has become a useful approach to many ER+ breast cancers. The aim of this review is to provide an update on the current state of art regarding the present and the future role of NET.
内分泌治疗（ET）已成为雌激素受体阳性（ER+）乳腺癌的一种有效治疗方法，可降低复发率并提高生存率。术前化疗（NCT）已成为治疗大型、局部晚期或高危肿瘤的常见管理方式。然而，通常预计ER+肿瘤对NCT的反应不佳。主要在老年女性中进行的原发性ET取得的良好效果促使人们对其他年龄段进行研究，如今新辅助内分泌治疗（NET）已成为许多ER+乳腺癌的一种有效治疗方法。本综述的目的是提供关于NET当前现状以及其当前和未来作用的最新信息。
